| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1
Division of Body Imaging and MRI, Department of Radiology, University of
Florida College of Medicine, Box 100374, 1600 S.W. Archer Rd., Gainesville, FL
32610.
2
Present address: Department of Radiology, Frimley Park Hospital, Portsmouth
Rd., Frimley, Camberley, Surrey, GU16 5UJ, United Kingdom.
3
Department of Radiology, Brigham and Women's Hospital, Harvard Medical School,
75 Francis St., Boston, MA 02115.
OBJECTIVE. The purpose of this study was to evaluate whether ferumoxides-enhanced MR imaging of focal hepatic lesions provides distinctive signal intensity and lesion-to-liver contrast changes for benign and malignant lesions, helping to further characterize and differentiate these lesions.
MATERIALS AND METHODS. Data analysis was performed on 70 patients, with previously identified focal hepatic lesions, who underwent MR imaging of the liver before and after IV administration of ferumoxides (10 µmol Fe/kg). Lesions analyzed with pathologically proven diagnoses included metastases (n = 40), hepatocellular carcinoma (n = 11), cholangiocarcinoma (n = 6), hemangioma (n = 4), focal nodular hyperplasia (n = 6), and hepatocellular adenoma (n = 3). Response variables measured and statistically compared included the percentage of signal-intensity change and lesion-to-liver contrast.
RESULTS. Focal nodular hyperplasia showed significant signal intensity loss on ferumoxides-enhanced T2-weighted images (mean, -43% ± 6.7%, p < 0.01). All other lesion groups showed no statistically significant change in signal intensity on ferumoxides-enhanced T2-weighted images, although signal intensity loss was seen in some individual hepatocellular adenomas (mean, -6.6% ± 24.0%) and hepatocellular carcinomas (mean, -3.3% ± 10.3%). All lesions, with the exception of hepatocellular carcinoma, had a marked increase in lesion-to-liver contrast on ferumoxides-enhanced T2-weighted images, which was statistically significant for metastases and hemangioma (p < 0.02).
CONCLUSION. Focal nodular hyperplasia shows significant decrease in signal intensity on ferumoxides-enhanced T2-weighted images, which may aid in the differentiation of focal nodular hyperplasia from other focal hepatic lesions. Other lesions, namely, hepatocellular adenoma and carcinoma, can have reticuloendothelial uptake, but usually to a lesser degree than that of focal nodular hyperplasia.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  M.-J. Kim, J. H. Kim, J. Y. Choi, S. H. Park, J.-J. Chung, K. W. Kim, and D. G. Mitchell Optimal TE for SPIO-enhanced gradient-recalled echo MRI for the detection of focal hepatic lesions. Am. J. Roentgenol., September 1, 2006; 187(3): W255 - W266. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C-S Li, R-C Chen, H-Y Tu, L-S Shih, T-A Zhang, J-M Lii, W-T Chen, S-J Duh, and L-C Chiang Imaging well-differentiated hepatocellular carcinoma with dynamic triple-phase helical computed tomography Br. J. Radiol., August 1, 2006; 79(944): 659 - 665. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Lutz, J. K. Willmann, K. Goepfert, B. Marincek, and D. Weishaupt Hepatocellular Carcinoma in Cirrhosis: Enhancement Patterns at Dynamic Gadolinium- and Superparamagnetic Iron Oxide-enhanced T1-weighted MR Imaging Radiology, November 1, 2005; 237(2): 520 - 528. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. J. Pijl, J. Doornbos, M. N. J. M. Wasser, H. C. van Houwelingen, R. A. E. M. Tollenaar, and J. L. Bloem Quantitative Analysis of Focal Masses at MR Imaging: A Plea for Standardization Radiology, June 1, 2004; 231(3): 737 - 744. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kumano, T. Murakami, T. Kim, M. Hori, A. Okada, T. Sugiura, Y. Noguchi, S. Kawata, K. Tomoda, and H. Nakamura Using Superparamagnetic Iron Oxide-Enhanced MRI to Differentiate Metastatic Hepatic Tumors and Nonsolid Benign Lesions Am. J. Roentgenol., November 1, 2003; 181(5): 1335 - 1339. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-J. Kim, J. H. Kim, J.-J. Chung, M. S. Park, J. S. Lim, and Y. T. Oh Focal Hepatic Lesions: Detection and Characterization with Combination Gadolinium- and Superparamagnetic Iron Oxide-enhanced MR Imaging Radiology, September 1, 2003; 228(3): 719 - 726. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Bluemke, T. M. Weber, D. Rubin, E. E. de Lange, R. Semelka, R. D. Redvanly, J. Chezmar, E. Outwater, R. Carlos, S. Saini, et al. Hepatic MR Imaging with Ferumoxides: Multicenter Study of Safety and Effectiveness of Direct Injection Protocol Radiology, August 1, 2003; 228(2): 457 - 464. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Lim, D. Choi, S. K. Cho, S. H. Kim, W. J. Lee, H. K. Lim, C. K. Park, S. W. Paik, and Y. I. Kim Conspicuity of Hepatocellular Nodular Lesions in Cirrhotic Livers at Ferumoxides-enhanced MR Imaging: Importance of Kupffer Cell Number Radiology, September 1, 2001; 220(3): 669 - 676. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Levy and P. R. Ros Invited Commentary RadioGraphics, July 1, 2001; 21(4): 892 - 894. [Full Text] [PDF]
|
|
|
|
|
|
L. Grazioli, G. Morana, M. P. Federle, G. Brancatelli, M. Testoni, M. A. Kirchin, K. Menni, L. Olivetti, N. Nicoli, and C. Procacci Focal Nodular Hyperplasia: Morphologic and Functional Information from MR Imaging with Gadobenate Dimeglumine Radiology, December 1, 2001; 221(3): 731 - 739. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
